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Abstract  
Economic evaluations have a widespread application in many areas of clinical research and play 
a key role in clinical decision-making process. However, economic analyses have been 
sometimes used to produce new “evidence” that is not adequately tested in the target population. 
This is the case of data arising from a systematic review of clinical trials evaluating the use of 
direct acting oral anticoagulants (DOACs) for the prevention of stroke in patients with atrial 
fibrillation. Taking into account this example, here we discuss the concerns raised by the 
improper interpretation of the results. Our conclusions are threefold. Data from economic 
analyses should not be shifted to a clinical recommendation. Simulation models should not be 
used to generate new “evidence”, that is not supported by experimental data and is misleading. 
Clinical judgment is therefore pivotal to interpret results emerging from economic analyses. 
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Perspective Article 
Since the publication of the foundations of cost-effectiveness analysis (CEA) for health and 
medical practices in the 1970s,1 this approach has been widely applied to health technologies and 
pharmaceuticals. However, criticism has emerged regarding the influence of conflicts of 
interest,2,3 the varying degrees of precision, power of data and analytic methods,4 and the 
difference between clinical evidence obtained in randomized controlled trials (RCTs), which aim 
to receive regulatory approval, and clinical effectiveness in real-world practice.5,6 The main 
concerns are that these economic analyses could be used to produce new evidence that is often 
not adequately tested in the target population, instead of using available evidence that emerges 
from clinical trials to add useful information for the efficient allocation of resources. 
In 1996, O’Brien noted that although RCTs provide the highest level of clinical evidence, 
these trials are designed to measure efficacy in a restricted population (i.e., using drugs in 
clinical practice).5 Thus, applying the results of RCTs to assessments of clinical effectiveness in 
real-world practice may be challenging. If RCTs are not the optimal source of efficacy measures 
in assessing clinical effectiveness, compared to that of data published twenty years ago, the 
strength of clinical evidence is currently lower in several therapeutic areas. Furthermore, many 
registrative trials are not comparative (i.e., single arm, particularly among orphan drugs), are 
based on surrogate markers that may not correlate well with the outcome of interest,7 or are 
designed as a non-inferiority trial; the frequency of such trials has increased by a factor of 6 
during the past decade.8 
According to currently available efficacy data from registrative clinical trials, the risk that 
CEA may generate new evidence that is not supported in the clinical setting is high. Thus, 
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alternative options that do not differ in clinical efficacy likely differ in models comparing 
effectiveness and cost-effectiveness. 
With this regard, Lopez-Lopez et al.9 performed a systematic review of RCTs evaluating 
the use of direct acting oral anticoagulants (DOACs), vitamin K antagonists, or antiplatelet drugs 
for the prevention of stroke in patients with atrial fibrillation. The systematic review included 23 
randomized trials involving 94656 patients, and the authors performed a network meta-analysis. 
Then, a CEA was performed based on a discrete-time multistate Markov model. The main aim of 
the analysis was to indirectly compare the use of DOACs and warfarin for the prevention of 
stroke in patients with atrial fibrillation and recommend a rank order for the use of DOACs based 
on efficacy, safety and cost. The first conclusion of this systematic review was that DOACs, as a 
class, reduce the risk of stroke and all-cause mortality and are safer than warfarin in terms of 
major and intracranial bleeding at doses that maintain an international normalized ratio (INR) of 
2.0 to 3.0. This result was unexpected since DOACs have been authorized by both the European 
Medicine Agency and Food and Drug Administration based on evidence that DOACs are not 
inferior to warfarin. 
The second conclusion was that since 5 mg apixaban twice daily ranks the highest in the 
balance of efficacy, safety, and cost, thus policy makers, healthcare providers, and patients 
should consider apixaban the first choice among DOACs for the prevention of stroke in most 
patients with atrial fibrillation. 
According to these conclusions, the translation of the results of Lopez-Lopez et al.’s9 
CEA into clinical recommendations indicates that 5 mg apixaban twice daily should be 
considered as first choice in the prescription of DOACs, while the first conclusion is already 
included in the main updated clinical guidelines.10 No clinical guideline supports the use of any 
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specific DOAC as the first choice due to several therapeutic reasons; . for For instance, different 
DOACs may be more appropriate than others in different settings; therefore, each DOAC may be 
more appropriate according to the individual patient profile, i.e., impaired renal function, history 
of ischaemic heart disease, peripheral arterial disease, etc, as reviewed elsewhere.11 
Overall, a first-choice drug other than apixaban could be selected for several therapeutic 
reasons, and this alternative is likely equally cost effective for patient subgroups; consequently, 
the CEA on DOACs generated new evidence that is not supported by experimental data, which is 
a critical issue; thus, identifying the step in the analysis that could affect the CEA’s conclusions 
and result in potentially misleading clinical recommendations is relevant. 
The first step is the indirect comparisons among the DOACs using a network meta-
analysis. Tables 1 and 2 show the results of the network meta-analysis performed to indirectly 
compare the use of DOACs in regard to the outcomes of stroke, myocardial infarction, mortality, 
and bleeding in patients with atrial fibrillation (data published by Lopez-Lopez et al.9; the data 
reported in the tables only reflect the indirect comparisons, i.e., the direct comparison with 
warfarin was excluded). Based on the indirect comparison using a network meta-analysis, no 
DOAC is better than another in terms of efficacy in stroke prevention and risk of adverse events 
(Tables 1 and 2). In a few cases, the odds ratios were statistically significant; however the 
significant differences highlighted may have had a high probability of occurring by chance, the 
so-called family-wise error. Indeed, these estimates were obtained without adjusting for multiple 
comparisons, therefore, the observed statistically significant odds ratios may be not due to 
systematic differences among DOACs. This could be a critical issue for the network meta-
analysis performed giving rise to false positive results.12 As a whole, this finding is not 
unexpected based on the recommendation of the main clinical guidelines.10;13  
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Table 3 shows the results of the CEA of licensed products for the prevention of stroke in patients 
with atrial fibrillation from Lopez-Lopez et al.9 First, the Markov model predicted insignificant 
differences among DOACs in the expected mean quality-adjusted life years (QALYs). This 
result is consistent with the results of the network meta-analysis. However, whether meta-
analysis of RCTs supports a favourable risk–benefit profile of DOACs compared to warfarin,14 
no significant differences were obtained from the modelling of the expected QALYs in patients 
treated with DOACs and warfarin.  
DOAC anticoagulation treatment is easier to manage than that of warfarin, thus providing 
greater opportunities to improve the quality of life15 due to the possibility of not periodically 
monitoring the INR, which is the main reason for the reimbursement of DOACs by public 
healthcare. Furthermore, a product that only requires administration once daily may provide 
certain advantages in terms of medication adherence compared with products that require twice 
daily administration. In contrast, a twice daily administration schedule of molecules with a 
shorter half-life may provide an advantage in managing the risk of bleeding during the waiting 
period for emergency surgery. 
Overall, more than 80% of the variability in the point estimates of the QALYs with all 
DOACs overlapped with that of warfarin  (i.e.: percentage of 95% CI overlapped with that of 
warfarin). According to the overall results of both the network meta-analysis and the Markov 
model, no healthcare benefit can be attributed more to one DOAC molecule than to another. 
Thus, the less expensive DOAC molecule should be considered a better option since it 
can provide the same healthcare benefit at a lower cost. Dabigatran had the lowest mean cost 
(Table 3); however, this conclusion could be incorrect for two reasons. First, no statistically 
significant differences were observed for the mean expected cost of each DOAC and that of 
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warfarin (the 95% confidence interval of the incremental expected cost of each DOAC crossed 
zero). Second, more than 90% of the variability in the point estimates of the cost of each DOAC 
overlapped that of warfarin. Based on the results obtained from the analysis performed by 
Lopez-Lopez et al.,9 the main conclusion should be that the analysis confirms the suggestions of 
the main clinical guidelines,10;13 which do not support the preferential use of a DOAC over 
another in the same class. Furthermore, no evidence supports the lower total cost of a molecule 
compared to others. 
Notably, the cost difference among the DOACs depends on the listed price of the 
product. Thus, the rank order and magnitude of the cost differences among the DOACs may 
change considering the final prices that institutional payers actually pay,16 which could also 
affect the transfer of cost-effectiveness results from one country to another in a healthcare 
context. 
Regardless of the limitations related to price and the transfer of cost-effectiveness results 
among different countries, the analysis included a step that computed the incremental net benefit 
(INB) of each DOAC compared to that of warfarin by combining cost data and QALYs from 
distributions that almost completely overlapped, which did not permit the identification of a 
better alternative option in regard to QALYs or total cost. Due to this methodological approach, 
the authors drew an incorrect conclusion regarding the use of 5 mg apixaban twice daily based 
on the 95% confidence interval of the INB, which did not cross zero. The lower limit was 93.5% 
lower than the mean estimate (£7 533, 95% CI: £490-18228, considering a threshold of £20 000 
per QALY), and the upper limit was 142% higher than the mean estimate. Furthermore, the 
probability that 5 mg apixaban was the most cost-effective option always remained under 60% of 
any value of willingness to pay.9 
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In conclusion, economic evaluation has gained a widespread application in many areas of clinical 
research. In particular, health economics help address clinical decision-making process. 
However, the example described here concerning the use of DOACs in the prevention of 
thromboembolic complications suggests the need to avoid both misleading interpretations in 
transferring results into clinical recommendation and the generation (by the mean of simulation 
models) of new evidences, that are not supported by experimental data. This criticism has been 
already highlighted in the oncological context, where the acceptance by national health 
authorities of modelled data for reimbursement purpose may create a biased incentive for 
pharmaceutical companies to substitute RCTs that directly assess hard endpoints.17 In this way, it 
is essential that the clinician acquires skills to critically evaluate the information and results 
emerging from economic modelling.  
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Table 1. Indirect comparisons using a network meta-analysis of recommended doses of DOACs evaluated in a phase III trial investigating stroke, 
myocardial infarction, and mortality outcomes in patients with atrial fibrillation. 
Comparison of recommended doses of 
DOACs evaluated in a phase III trial 
Stroke or systemic 
embolism 
Ischaemic stroke 
Myocardial 
infarction 
All-cause mortality 
Odds ratio* (95% CI) Odds ratio* (95% CI) 
Odds ratio* (95% 
CI) 
Odds ratio* (95% 
CI) 
Dabigatran 150 mg twice daily and 
apixaban 5 mg twice daily 
0.82 (0.62 to 1.08) 0.83 (0.59 to 1.16) 1.48 (0.98 to 2.22) 1.00 (0.84 to 1.19) 
Edoxaban 60 mg once daily and 
apixaban 5 mg twice daily 
1.09 (0.87 to 1.39) 1.10 (0.83 to 1.46) 1.10 (0.76 to 1.58) 1.03 (0.89 to 1.20) 
Rivaroxaban 20 mg once daily and 
apixaban 5 mg twice daily 
1.11 (0.87 to 1.41) 1.01 (0.74 to 1.38) 0.92 (0.63 to 1.34) 0.94 (0.76 to 1.17) 
Edoxaban 60 mg once daily and 
dabigatran 150 mg twice daily 
1.33 (1.02 to 1.75) 1.33 (0.97 to 1.83) 0.74 (0.50 to 1.09) 1.03 (0.87 to 1.22) 
Rivaroxaban 20 mg once daily and 
dabigatran 150 mg twice daily 
1.35 (1.03 to 1.78) 1.22 (0.87 to 1.73) 0.62 (0.41 to 0.93) 0.94 (0.74 to 1.18) 
Table 1
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Rivaroxaban 20 mg once daily and 
edoxaban 60 mg once daily 
1.01 (0.80 to 1.27) 0.92 (0.69 to 1.23) 0.84 (0.59 to 1.20) 0.91 (0.73 to 1.13) 
Modified from Lopez-Lopez et al.9; *statistically significant odds ratios are shown in bold 
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Table 2. Indirect comparisons using a network meta-analysis of recommended doses of DOACs evaluated in a phase III trial investigating bleeding 
outcomes in patients with atrial fibrillation. 
Comparison of recommended doses of 
DOACs evaluated in a phase III trial 
Major Intracranial Gastrointestinal Clinically relevant 
Odds ratio (95% CI) Odds ratio (95% CI) 
Odds ratio (95% 
CI) 
Odds ratio (95% CI) 
Dabigatran 150 mg twice daily and 
apixaban 5 mg twice daily 
1.33 (1.09 to 1.62) 0.96 (0.58 to 1.60) 1.71 (1.21 to 2.43) 2.32 (0.74 to 8.63) 
Edoxaban 60 mg once daily and 
apixaban 5 mg twice daily 
1.11 (0.92 to 1.35) 1.09 (0.69 to 1.70) 1.38 (1.00 to 1.92) 1.24 (1.09 to 1.42) 
Rivaroxaban 20 mg once daily and 
apixaban 5 mg twice daily 
1.45 (1.19 to 1.78) 1.55 (0.97 to 2.49) 1.66 (1.19 to 2.33) 1.53 (1.33 to 1.75) 
Edoxaban 60 mg once daily and 
dabigatran 150 mg twice daily 
0.84 (0.69 to 1.02) 1.13 (0.69 to 1.87) 0.81 (0.60 to 1.09) 0.54 (0.14 to 1.68) 
Rivaroxaban 20 mg once daily and 
dabigatran 150 mg twice daily 
1.10 (0.90 to 1.34) 1.61 (0.96 to 2.72) 0.97 (0.71 to 1.33) 0.66 (0.18 to 2.07) 
Rivaroxaban 20 mg once daily and 1.31 (1.07 to 1.59) 1.43 (0.90 to 2.26) 1.21 (0.90 to 1.60) 1.23 (1.10 to 1.37) 
Table 2
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edoxaban 60 mg once daily 
Modified from Lopez-Lopez et al.9; *statistically significant odds ratios are shown in bold 
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Table 3. Cost effectiveness of licensed products used for the prevention of stroke in patients with atrial fibrillation from Lopez-Lopez et al.9 
Expected (mean) values are reported (95% confidence intervals). Incremental values are relative to a warfarin international normalized ratio (INR) 
of 2.0-3.0. 
  
Warfarin 
INR (2.0-3.0) 
Apixaban 5 mg 
twice daily 
Dabigatran 150 
mg twice daily 
Edoxaban 60 mg 
once daily 
Rivaroxaban 20 mg 
once daily 
       
Total costs (£)      
Expected 
24 418 
(12 189 to 50 
365) 
23 340 
(12 842 to 45 
753) 
23 064 
(12 674 to 46 
075) 
23 985 
(13 098 to 46 
319) 
24 841 
(13 198 to 47 603) 
incremental expected NA 
-1 078 
(-7 626 to 2 568) 
-1 354 
(-8 049 to 2 
273) 
-433 
(-6 430 to 3 619) 
422 
(-4 730 to 5 104) 
QALYs      
Expected 
5.166 
(3.629 to 6.541) 
5.488 
(3.841 to 6.795) 
5.416 
(3.817 to 6.701) 
5.405 
(3.819 to 6.678) 
5.451 
(3.824 to 6.797) 
Table 3
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incremental expected NA 
0.323 
(-0.015 to 0.814) 
0.251 
(-0.080 to 
0.703) 
0.239 
(-0.112 to 0.684) 
0.285 
(-0.068 to 0.810) 
Expected incremental 
net benefit at threshold 
(£) 
     
£20 000 NA 
7 533 
(490 to 18 228) 
6 365 
(-168 to 17 039) 
5 212 
(-894 to 14 826) 
5 279 
(-1 097 to 15 180) 
£30 000 NA 
10 760 
(576 to 25 861) 
8 871 
(-597 to 23 402) 
7 601 
(-1 556 to 20 987) 
8 130 
(-1 399 to 22 819) 
Modified from Lopez-Lopez et al.9; NA=not applicable; QALY=quality-adjusted life year 
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This is a “perspective article” in which we discuss the concerns raised by the improper 
interpretation of data from economic analyses. We therefore discuss the example of a published 
systematic review of clinical trials evaluating the use of direct acting oral anticoagulants for the 
prevention of stroke in patients with atrial fibrillation. We conclude that simulation models should 
not be used to generate new “evidence”, that is not supported by experimental data. Results from 
economic analyses should not be translated into a clinical recommendation and clinical judgment 
is pivotal for a proper interpretation.  
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